Altre lingue CSPC Pharmaceutical Group Ltd.

Azioni

1093

HK1093012172

Mercato chiuso - Hong Kong S.E. Altri mercati azionari 10:08:17 17/05/2024			Variaz. 5gg	Var. 1 gen.
6,62 ^HKD	-1,05%		-3,50%	-8,82%

17/05	CSPC Pharma ottiene l'autorizzazione per la sperimentazione clinica in Cina di un farmaco per le malattie legate al metabolismo	MT
17/05	CSPC Pharmaceutical Group Limited annuncia che il farmaco anticorpo monoclonale ricombinante anti-Klotho completamente umano (JMT202) ha ottenuto l'approvazione dall'Amministrazione Nazionale dei Prodotti Medici della Repubblica Popolare Cinese	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

CSPC Pharma Gets Clearance for China Clinical Trial of Drug for Metabolism-Related Diseases	17/05
CSPC Pharmaceutical Group Limited Announces Recombinant Fully Human Anti-bKlotho Monoclonal Antibody Drug Obtains Approval from National Medical Products Administration of the People's Republic of China	17/05
CSPC Pharma's Flu Medication Gets Registration Approval in China	14/05
Cspc Pharmaceutical Group Limited Announces That the Peramivir Injection (15Ml:0.15G) (The "Product") Developed by the Group Has Obtained Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China, and Is Deemed to Have Passed the Consistency Evaluation of Quality and Efficacy for Generic Drugs	14/05
CSPC Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended 31 December 2023	26/04
CSPC Pharmaceutical Group Limited Announces Highly Selective Mat2A Inhibitor Obtains Clinical Trial Approval in the U.S	26/04
CSPC Pharmaceutical's EBT Buys 8.5 Million Shares	24/04
CSPC Pharmaceutical Group Limited and CSPC Holdings Company Limited Enter into Master Sales Agreement	19/04
China's drugmakers can't sell mRNA shots but haven't quit yet	19/04
CSPC Pharmaceutical Group Limited commences an Equity Buyback Plan for 1,190,321,973 shares, representing 10% of its issued share capital, under the authorization approved on May 31, 2023.	16/04
CSPC Pharma Secures Chinese Nod for Weight Managment Drug Trials	26/03
CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval Granted by the National Medical Products Administration	25/03
CSPC Pharmaceutical’ Blood Sugar Drug Gets Registration Approval from Chinese Regulator	22/03
CSPC Pharmaceutical Group Limited Announces Dapagliflozin Tablets Obtains Drug Registration Approval	22/03
CSPC Pharmaceutical's Cancer Drug Gets China Nod for Clinical Trials	21/03
CSPC Pharmaceutical Group Limited Announces Antibody-Drug Conjugate SYS6023 Obtains Clinical Trial Approval by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China	20/03
CSPC Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 26 June 2024	20/03
CSPC Pharmaceutical's Profit Falls 4% on Lower Revenue, Misses Estimates	20/03
CSPC Pharmaceutical Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	20/03
CSPC Pharma Obtains Clinical Trial Approval in China for Anti-Tumor Drug	19/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue CSPC Pharmaceutical Group Ltd.

Azioni

1093

HK1093012172

Altre lingue

Filtri